151. Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents.
- Author
-
Tan SSN, Fong AYY, Mejin M, Gerunsin J, Kong KL, Chin FYY, Tiong LL, Lim MSH, Asri S, Khiew NZ, Voon CY, Mohd Amin NH, Cham YL, Koh KT, Oon YY, and Ong TK
- Subjects
- Alleles, Clopidogrel, Cohort Studies, Drug-Eluting Stents adverse effects, Female, Genotype, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors therapeutic use, Risk Factors, Ticlopidine adverse effects, Ticlopidine therapeutic use, Cardiovascular Diseases chemically induced, Cardiovascular Diseases genetics, Cytochrome P-450 CYP2C19 genetics, Drug-Related Side Effects and Adverse Reactions genetics, Platelet Aggregation Inhibitors adverse effects, Polymorphism, Genetic genetics, Ticlopidine analogs & derivatives
- Abstract
Background: Patients undergoing elective percutaneous coronary intervention (PCI) with drug-eluting stents (DES) who have impaired clopidogrel response, have a higher risk of subsequent major adverse cardiovascular events (MACE)., Aim of the Study: To establish the relationship between CYP2C19 genotype, clopidogrel responsiveness and 1-year MACE., Materials & Methods: Aspirin/clopidogrel responses were assessed with Multiplate Analyzer and CYP2C19*2 allele by SpartanRx., Results: A total of 42.0% carried ≥1 CYP2C19*2 allele. Prevalences of aspirin and clopidogrel high on-treatment platelet reactivity (HPR; local cutoffs: 300 AU*min for aspirin and 600 AU*min for clopidogrel) were 11.5% and 19.8% respectively. In multivariate ana-lysis, clopidogrel HPR was found to be an independent predictor for 1-year MACE (adj HR: 3.48, p = 0.022 )., Conclusion: Having clopidogrel HPR could be a potentially modifiable risk factor guided by phenotyping.
- Published
- 2017
- Full Text
- View/download PDF